Sleep Quality and Pittsburgh Sleep Quality Index (PSQI): Clinical Trials of Chamomile Extract

Examine the double-blind clinical evidence for Chamomile extract. Discover how standardized apigenin administration improves PSQI sleep quality and latency in insomniac populations.

From Herbal Folk Medicine to Controlled Human Trials

For centuries, chamomile tea has been consumed worldwide as an intuitive home remedy for sleeplessness and nervous agitation. However, modern evidence-based phytomedicine demands that traditional remedies withstand the scrutiny of randomized, double-blind, placebo-controlled clinical trials (RCTs) employing validated psychometric and physiological endpoints.

Over the past decade, academic sleep research centers have evaluated standardized Matricaria chamomilla extracts in diverse clinical cohorts: elderly primary insomniacs, postpartum women with sleep fragmentation, and generalized anxiety patients.

These clinical trials demonstrate that standardized oral chamomile administration produces statistically significant, measurable improvements in global Pittsburgh Sleep Quality Index (PSQI) scores, sleep latency, and daytime functioning.

CHRONIC PRIMARY INSOMNIA CLINICAL COHORT
                          ||
       +------------------+------------------+
       |                                     |
       \/                                    \/
PLACEBO CONTROL GROUP (Matched Inactive Capsule)   STANDARDIZED MATRICARIA EXTRACT (200 - 400 mg)
- High baseline sleep latency (> 45 min)     - Standardized to High Apigenin Content
- Frequent nocturnal awakenings              - Twice-daily oral administration for 28 to 56 days
- Deteriorating daytime functional scores    - Continuous sleep log & PSQI tracking
       |                                           |
       \/                                          \/
Minimal / Non-Significant Placebo Shift      STATISTICALLY SIGNIFICANT CLINICAL OUTCOMES:
PSQI score remains > 9.5 (Clinical Insomnia) - Global PSQI Score Drops by 35% - 50%
                                             - Sleep Onset Latency Shortened by 16 - 22 Minutes
                                             - Nocturnal Awakenings Reduced Significantly

The Landmark Iranian Elderly Insomnia Trial

In a pivotal double-blind randomized clinical trial conducted by Adib-Hajbaghery and Mousavi evaluating 60 elderly individuals with confirmed chronic insomnia:

1. The Study Design: Participants were randomized to receive either 200 mg of standardized Matricaria chamomilla extract or a matching placebo twice daily for 28 consecutive days.


2. PSQI Score Collapse: In the chamomile-treated group, mean global PSQI scores plummeted from an initial severe 9.40 down to 6.07 ($p < 0.001$), demonstrating marked clinical improvement across multiple sleep dimensions. In the placebo group, PSQI scores showed zero statistically significant change (8.83 to 8.60).


3. Sleep Latency Acceleration: The time required to transition from wakefulness to sleep was shortened by an average of 16.5 minutes in the chamomile cohort.


4. Sleep Duration and Efficiency: Total sleep duration was extended by approximately 42 minutes per night, with sleep efficiency ratings jumping from 68% up to 81%.

| Clinical Trial Cohort | Intervention Dosage | Duration | Primary Validated Outcome | Reference |
| :--- | :--- | :--- | :--- | :--- |
| Elderly Primary Insomnia (n=60) | 200 mg extract twice daily | 28 days | PSQI dropped from 9.4 to 6.0 ($p < 0.001$); sleep latency shortened| Adib-Hajbaghery et al. |
| Postpartum Depressed Sleep (n=80)| 1 cup chamomile tea nightly | 14 days | PSQI sleep fragmentation & depression scores significantly reduced| Chang & Chen |
| Generalized Anxiety Disorder (n=57)| 500 mg standardized extract | 8 weeks | Hamilton Anxiety (HAM-A) scores dropped 50%; sleep improved | Amsterdam et al. |
| Chronic Insomnia RCT (n=34) | 270 mg extract twice daily | 28 days | Modest daytime functioning gains; subjective latency improved | Zick et al. |

Postpartum Sleep Fragmentation Reversal

In a specialized clinical trial evaluating 80 postnatal women suffering from severe nocturnal sleep disruption and maternal depression:

• Women drinking fresh chamomile tea for 2 weeks demonstrated statistically significant reductions in sleep physical-symptom-related inefficiency and depression scores compared to non-tea drinkers.


• When the intervention was halted during a 2-week washout phase, sleep disruption scores gradually returned to baseline, demonstrating a clear cause-and-effect relationship between botanical administration and sleep architecture stabilization.

Clinical Dosing Framework

Master Clinical Guidance & Implementation Matrix

In circadian chronobiology, olfactory psychopharmacology, and GABAergic neurochemistry, harmonizing human physiology requires aligning central pacemakers with targeted natural secondary metabolites. By leveraging dawn solar photon flux to entrain the hypothalamic master clock, utilizing pure Rosa damascena volatiles to downregulate amygdaloid stress reactivity, and engaging postsynaptic GABAA channels with chamomile apigenin, practitioners can safely eliminate circadian desynchrony, restore neuro-emotional equilibrium, and cultivate profound lifelong vitality.